Keywords Angiotensin II receptor blockers . Angiotensinconverting enzyme inhibitors . End-stage renal disease . Multiple treatment comparisons . Nephropathy . Network meta-analysis . Reno-protective effect . Type 2 diabetes Abbreviations ACEI ACE inhibitor ARB Angiotensin II receptor blocker RAAS Renin-angiotensin-aldosterone system To the Editor: The network meta-analysis of renoprotective effects of renin-angiotensin-aldosterone system (RAAS) blockers in type 2 diabetic patients reported by Vejakama and colleagues [1] suggests that RAAS blockers are more efficacious than other antihypertensive drugs or placebo. In my opinion, the network meta-analysis contains important limitations and urge caution when making inferences from the results. The decision not to provide data separately for ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) can be problematic. Here, I concentrate on the authors' finding of a lower risk of end-stage renal disease for ACEI/ARB compared with active drugs and placebo. For the direct meta-analysis comparing ACEIs/ARBs with active controls (six trials), the meta-RR was 0.82 (95% CI 0.64, 1.05), which is consistent with the value observed in a single trial of irbesartan (RR 0.80; 95% CI 0.62, 1.04) [2] . In my opinion, Vejakama and colleagues should clarify why this finding should be extrapolated to all RAAS blockers. Their network meta-analysis cannot answer whether ARB therapy provides an improvement over that afforded by ACEIs (or vice versa). Data by trial in the journal web appendix (see electronic supplementary material Table 1 ) allows the following explanation by use of simple conventional network analysis. When examining network geometry, one can observe that very few placebo-controlled trials (or with an alternative common comparator) are available (Fig. 1a) . Along the same line, trials have been conducted over different lengths of time; explaining why there are different amounts of evidence and why the antihypertensive agents have not been compared extensively against each other (comparator preference biases) [3] . On the other hand, the trials included in the meta-analysis might not reflect treatment selection in real-world clinical practice (e.g. ACEI vs ARB) (Fig. 1b) and, in fact, all antihypertensive drugs are not indicated for the prevention of chronic renal failure in diabetic patients. However, recent data are available for several other agents not included in the analyses (e.g. olmesartan) [4] . Useful network meta-analysis requires that there is a comprehensive network of pair-wise comparisons that connects each (competitive) agent to every other, providing therefore meaningful inferences on the comparative efficacy of treatments.
To the Editor: The network meta-analysis of renoprotective effects of renin-angiotensin-aldosterone system (RAAS) blockers in type 2 diabetic patients reported by Vejakama and colleagues [1] suggests that RAAS blockers are more efficacious than other antihypertensive drugs or placebo. In my opinion, the network meta-analysis contains important limitations and urge caution when making inferences from the results. The decision not to provide data separately for ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) can be problematic. Here, I concentrate on the authors' finding of a lower risk of end-stage renal disease for ACEI/ARB compared with active drugs and placebo. For the direct meta-analysis comparing ACEIs/ARBs with active controls (six trials), the meta-RR was 0.82 (95% CI 0.64, 1.05), which is consistent with the value observed in a single trial of irbesartan (RR 0.80; 95% CI 0.62, 1.04) [2] . In my opinion, Vejakama and colleagues should clarify why this finding should be extrapolated to all RAAS blockers. Their network meta-analysis cannot answer whether ARB therapy provides an improvement over that afforded by ACEIs (or vice versa). Data by trial in the journal web appendix (see electronic supplementary material Table 1 ) allows the following explanation by use of simple conventional network analysis. When examining network geometry, one can observe that very few placebo-controlled trials (or with an alternative common comparator) are available (Fig. 1a) . Along the same line, trials have been conducted over different lengths of time; explaining why there are different amounts of evidence and why the antihypertensive agents have not been compared extensively against each other (comparator preference biases) [3] . On the other hand, the trials included in the meta-analysis might not reflect treatment selection in real-world clinical practice (e.g. ACEI vs ARB) (Fig. 1b) and, in fact, all antihypertensive drugs are not indicated for the prevention of chronic renal failure in diabetic patients. However, recent data are available for several other agents not included in the analyses (e.g. olmesartan) [4] . Useful network meta-analysis requires that there is a comprehensive network of pair-wise comparisons that connects each (competitive) agent to every other, providing therefore meaningful inferences on the comparative efficacy of treatments.
Finally, since the equivalence of the renoprotective effects of all RAAS blockers is not well established, further clinical evidence including that from well designed doubleblind, active-comparator randomised controlled trials, comparative observational studies, or both, is needed on the treatment of patients with type 2 diabetes.
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